This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.
We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.
Lord (Paul) Drayson, CEO of Sensyne Health, commented:
“I am pleased to report that Sensyne has made significant commercial progress over the past six months and has achieved several key milestones in the development of its research partnerships with NHS Trusts and in its work for leading pharmaceutical companies applying Clinical AI to improve patient care and accelerate life sciences research. I am particularly pleased with the results we have been able to achieve during the COVID-19 pandemic.
In January we completed a £27.5 million fund-raising, signed an important strategic collaboration with Phesi Inc and in December launched our GDm-Health product in the United States. We have made a strong start to the New Year and are well placed to build on this momentum in 2021.”
Click here to view the full interim results.
OPERATING HIGHLIGHTS (INCLUDING POST PERIOD END)
Growth of anonymised NHS patient dataset to 6.8m records to achieve IPO target
Discovery Sciences: New commercial agreements expand relationships with pharmaceutical industry
Software Products: Clinical algorithm platform and remote monitoring products
Planned scaling and industrialisation of data platforms
Phesi Strategic Collaboration
Strengthening of Board and Senior Management team
FINANCIAL HIGHLIGHTS
Analyst and Investor briefing
Management will present the interim results for analysts and investors today at 13.00 GMT. There will be a simultaneous live conference call and webcast. For more details please contact radu@consilium-comms.com at Consilium Strategic Communications.
A replay of today’s webcast of the meeting and the presentation slides will be available on the investor section of Sensyne Health’s website after the event at https://www.sensynehealth.com/investors/investor-hub
Lord (Paul) Drayson, CEO of Sensyne Health, commented:
“I am pleased to report that Sensyne has made significant commercial progress over the past six months and has achieved several key milestones in the development of its research partnerships with NHS Trusts and in its work for leading pharmaceutical companies applying Clinical AI to improve patient care and accelerate life sciences research. I am particularly pleased with the results we have been able to achieve during the COVID-19 pandemic.
In January we completed a £27.5 million fund-raising, signed an important strategic collaboration with Phesi Inc and in December launched our GDm-Health product in the United States. We have made a strong start to the New Year and are well placed to build on this momentum in 2021.”
Click here to view the full interim results.
OPERATING HIGHLIGHTS (INCLUDING POST PERIOD END)
Growth of anonymised NHS patient dataset to 6.8m records to achieve IPO target
Discovery Sciences: New commercial agreements expand relationships with pharmaceutical industry
Software Products: Clinical algorithm platform and remote monitoring products
Planned scaling and industrialisation of data platforms
Phesi Strategic Collaboration
Strengthening of Board and Senior Management team
FINANCIAL HIGHLIGHTS
Analyst and Investor briefing
Management will present the interim results for analysts and investors today at 13.00 GMT. There will be a simultaneous live conference call and webcast. For more details please contact radu@consilium-comms.com at Consilium Strategic Communications.
A replay of today’s webcast of the meeting and the presentation slides will be available on the investor section of Sensyne Health’s website after the event at https://www.sensynehealth.com/investors/investor-hub
Lord (Paul) Drayson, CEO of Sensyne Health, commented:
“I am pleased to report that Sensyne has made significant commercial progress over the past six months and has achieved several key milestones in the development of its research partnerships with NHS Trusts and in its work for leading pharmaceutical companies applying Clinical AI to improve patient care and accelerate life sciences research. I am particularly pleased with the results we have been able to achieve during the COVID-19 pandemic.
In January we completed a £27.5 million fund-raising, signed an important strategic collaboration with Phesi Inc and in December launched our GDm-Health product in the United States. We have made a strong start to the New Year and are well placed to build on this momentum in 2021.”
Click here to view the full interim results.
OPERATING HIGHLIGHTS (INCLUDING POST PERIOD END)
Growth of anonymised NHS patient dataset to 6.8m records to achieve IPO target
Discovery Sciences: New commercial agreements expand relationships with pharmaceutical industry
Software Products: Clinical algorithm platform and remote monitoring products
Planned scaling and industrialisation of data platforms
Phesi Strategic Collaboration
Strengthening of Board and Senior Management team
FINANCIAL HIGHLIGHTS
Analyst and Investor briefing
Management will present the interim results for analysts and investors today at 13.00 GMT. There will be a simultaneous live conference call and webcast. For more details please contact radu@consilium-comms.com at Consilium Strategic Communications.
A replay of today’s webcast of the meeting and the presentation slides will be available on the investor section of Sensyne Health’s website after the event at https://www.sensynehealth.com/investors/investor-hub
Lord (Paul) Drayson, CEO of Sensyne Health, commented:
“I am pleased to report that Sensyne has made significant commercial progress over the past six months and has achieved several key milestones in the development of its research partnerships with NHS Trusts and in its work for leading pharmaceutical companies applying Clinical AI to improve patient care and accelerate life sciences research. I am particularly pleased with the results we have been able to achieve during the COVID-19 pandemic.
In January we completed a £27.5 million fund-raising, signed an important strategic collaboration with Phesi Inc and in December launched our GDm-Health product in the United States. We have made a strong start to the New Year and are well placed to build on this momentum in 2021.”
Click here to view the full interim results.
OPERATING HIGHLIGHTS (INCLUDING POST PERIOD END)
Growth of anonymised NHS patient dataset to 6.8m records to achieve IPO target
Discovery Sciences: New commercial agreements expand relationships with pharmaceutical industry
Software Products: Clinical algorithm platform and remote monitoring products
Planned scaling and industrialisation of data platforms
Phesi Strategic Collaboration
Strengthening of Board and Senior Management team
FINANCIAL HIGHLIGHTS
Analyst and Investor briefing
Management will present the interim results for analysts and investors today at 13.00 GMT. There will be a simultaneous live conference call and webcast. For more details please contact radu@consilium-comms.com at Consilium Strategic Communications.
A replay of today’s webcast of the meeting and the presentation slides will be available on the investor section of Sensyne Health’s website after the event at https://www.sensynehealth.com/investors/investor-hub
Lord (Paul) Drayson, CEO of Sensyne Health, commented:
“I am pleased to report that Sensyne has made significant commercial progress over the past six months and has achieved several key milestones in the development of its research partnerships with NHS Trusts and in its work for leading pharmaceutical companies applying Clinical AI to improve patient care and accelerate life sciences research. I am particularly pleased with the results we have been able to achieve during the COVID-19 pandemic.
In January we completed a £27.5 million fund-raising, signed an important strategic collaboration with Phesi Inc and in December launched our GDm-Health product in the United States. We have made a strong start to the New Year and are well placed to build on this momentum in 2021.”
Click here to view the full interim results.
OPERATING HIGHLIGHTS (INCLUDING POST PERIOD END)
Growth of anonymised NHS patient dataset to 6.8m records to achieve IPO target
Discovery Sciences: New commercial agreements expand relationships with pharmaceutical industry
Software Products: Clinical algorithm platform and remote monitoring products
Planned scaling and industrialisation of data platforms
Phesi Strategic Collaboration
Strengthening of Board and Senior Management team
FINANCIAL HIGHLIGHTS
Analyst and Investor briefing
Management will present the interim results for analysts and investors today at 13.00 GMT. There will be a simultaneous live conference call and webcast. For more details please contact radu@consilium-comms.com at Consilium Strategic Communications.
A replay of today’s webcast of the meeting and the presentation slides will be available on the investor section of Sensyne Health’s website after the event at https://www.sensynehealth.com/investors/investor-hub